Advertisement

Dupilumab in Atopic Dermatitis

  • Milagros Lázaro-Sastre
  • Asunción García-SánchezEmail author
  • Aída Gómez-Cardeñosa
  • Ignacio Dávila
Urticaria and Atopic Dermatitis (M Furue and T Nakahara, Section Editors)
  • 12 Downloads
Part of the following topical collections:
  1. Topical Collection on Urticaria and Atopic Dermatitis

Abstract

Purpose of review

Atopic dermatitis (AD) is a common chronic inflammatory relapsing skin disease that greatly affects the quality of life of patients and their relatives. Topical treatment represents the initial therapeutic option in AD, although in patients with severe AD that do not respond to first-line topical therapies treatment with systemic immunosuppressive drugs is usually required. New advances in the understanding of the immune pathogenesis of AD have led to the development of targeted therapies.

Recent findings

Dupilumab, the only biologic approved for AD treatment, is a fully human monoclonal antibody IgG4 directed to the α subunit of the interleukin-4 receptor (IL-4Rα), blocking the IL-4 and IL-13, both crucial cytokines of the Th2 pathway. It has shown a significant clinical efficacy with good tolerance.

Summary

In this review, we will discuss the results of recent clinical trials and real-life studies.

Keywords

Atopic dermatitis Dupilumab Biologics IL-4R Clinical trials 

Notes

Compliance with Ethical Standards

Conflict of Interest

Milagros Lázaro-Sastre declares that she has no conflict of interest.

Aída Gómez-Cardeñosa declares that she has no conflict of interest.

Maria Asunción García-Sánchez declares that she has no conflict of interest.

Ignacio Dávila has received payment for lectures including service on speaker bureaus from Allergy-Therapeutics, ALK-Abello, Astra-Zeneca, Diater, GSK, Leti, Merck, Novartis, Roche, Sanofi, and Teva; consultancy from ALK-Abello, Astra-Zeneca, GSK, Novartis, Sanofi, and Teva; and grants from Merck and Thermo Fisher Diagnostics.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Weidinger S, Novak N. Atopic dermatitis. Lancet Lond Engl. 2016;387(10023):1109–22.CrossRefGoogle Scholar
  2. 2.
    Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78–88.CrossRefGoogle Scholar
  3. 3.
    Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70(7):836–45.CrossRefGoogle Scholar
  4. 4.
    Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol JEADV. 2011;25(1):12–8.CrossRefGoogle Scholar
  5. 5.
    Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17–27.CrossRefGoogle Scholar
  6. 6.
    Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25(1):1–6.CrossRefGoogle Scholar
  7. 7.
    Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274–279.e3.CrossRefGoogle Scholar
  8. 8.
    Bieber T, Straeter B. Off-label prescriptions for atopic dermatitis in Europe. Allergy. 2015;70(1):6–11.CrossRefGoogle Scholar
  9. 9.
    Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–46.CrossRefGoogle Scholar
  10. 10.
    • Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–76 This paper focuses on the atopic dermatitis phenotypes, immunological background, and recent therapies.CrossRefGoogle Scholar
  11. 11.
    •• Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–72 This paper studies, in patients with moderate-to-severe atopic dermatitis, the effects of dupilumab on molecular/cellular lesional and nonlesional skin and systemic biomarkers of type 2.CrossRefGoogle Scholar
  12. 12.
    Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–51.CrossRefGoogle Scholar
  13. 13.
    Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;92(Suppl):44–7.Google Scholar
  14. 14.
    Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131(3):383–96.CrossRefGoogle Scholar
  15. 15.
    Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406–16.CrossRefGoogle Scholar
  16. 16.
    Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol. 1994;131(3):397–405.CrossRefGoogle Scholar
  17. 17.
    Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy. 2004;59(Suppl 78):86–92.CrossRefGoogle Scholar
  18. 18.
    Schram ME, Leeflang MMG, DEN Ottolander JPS, Spuls PI, Bos JD. Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol. 2011;38(9):850–8.PubMedGoogle Scholar
  19. 19.
    Hill MK, Kheirandish Pishkenari A, Braunberger TL, Armstrong AW, Dunnick CA. Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: a systematic review. J Am Acad Dermatol. 2016;75(5):906–17.CrossRefGoogle Scholar
  20. 20.
    Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group Exp Dermatol. 2001;10(1):11–8.CrossRefGoogle Scholar
  21. 21.
    Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106.CrossRefGoogle Scholar
  22. 22.
    Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2017;176(4):979–84.CrossRefGoogle Scholar
  23. 23.
    Stalder J-F, Bernier C, Ball A, De Raeve L, Gieler U, Deleuran M, et al. Therapeutic patient education in atopic dermatitis: worldwide experiences. Pediatr Dermatol. 2013;30(3):329–34.CrossRefGoogle Scholar
  24. 24.
    Vourc’h-Jourdain M, Barbarot S, Taieb A, Diepgen T, Ambonati M, Durosier V, et al. Patient-oriented SCORAD: a self-assessment score in atopic dermatitis. A preliminary feasibility study. Dermatol Basel Switz. 2009;218(3):246–51.CrossRefGoogle Scholar
  25. 25.
    Garg N, Silverberg JI. Epidemiology of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):281–8.CrossRefGoogle Scholar
  26. 26.
    Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatol Basel Switz. 1997;195(1):10–9.CrossRefGoogle Scholar
  27. 27.
    Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–7.CrossRefGoogle Scholar
  28. 28.
    Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226–32.CrossRefGoogle Scholar
  29. 29.
    Stalder J-F, Aubert H, Anthoine E, Futamura M, Marcoux D, Morren M-A, et al. Topical corticosteroid phobia in atopic dermatitis: international feasibility study of the TOPICOP score. Allergy. 2017;72(11):1713–9.CrossRefGoogle Scholar
  30. 30.
    Mailhol C, Lauwers-Cances V, Rancé F, Paul C, Giordano-Labadie F. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. Allergy. 2009;64(5):801–6.CrossRefGoogle Scholar
  31. 31.
    van Zuuren EJ, Fedorowicz Z, Arents BWM. Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol. 2017;177(5):1256–71.CrossRefGoogle Scholar
  32. 32.
    Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824–830.e6.CrossRefGoogle Scholar
  33. 33.
    Lowe AJ, Su JC, Allen KJ, Abramson MJ, Cranswick N, Robertson CF, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol. 2018;178(1):e19–21.CrossRefGoogle Scholar
  34. 34.
    Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818–23.CrossRefGoogle Scholar
  35. 35.
    Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol. 2005;152(1):130–41.CrossRefGoogle Scholar
  36. 36.
    Broeders JA, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol. 2016;75(2):410–419.e3.CrossRefGoogle Scholar
  37. 37.
    Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol JEADV. 2018;32(5):657–82.CrossRefGoogle Scholar
  38. 38.
    Silverberg JI. Atopic dermatitis treatment: current state of the art and emerging therapies. Allergy Asthma Proc. 2017;38(4):243–9.CrossRefGoogle Scholar
  39. 39.
    •• Werfel T. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018. Curr Opin Allergy Clin Immunol. 2018;18(5):432–7. This paper reviews the therapeutical targets that have recently been investigated and published in clinical trials on atopic dermatitis.Google Scholar
  40. 40.
    Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–9.CrossRefGoogle Scholar
  41. 41.
    Kovalenko P, DiCioccio AT, Davis JD, Li M, Ardeleanu M, Graham N, et al. Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL-4Rα, in atopic dermatitis patients and normal volunteers. CPT Pharmacometrics Syst Pharmacol. 2016;5(11):617–24.CrossRefGoogle Scholar
  42. 42.
    Ul-Haq Z, Naz S, Mesaik MA. Interleukin-4 receptor signaling and its binding mechanism: a therapeutic insight from inhibitors tool box. Cytokine Growth Factor Rev. 2016;32:3–15.CrossRefGoogle Scholar
  43. 43.
    Junttila IS, Creusot RJ, Moraga I, Bates DL, Wong MT, Alonso MN, et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat Chem Biol. 2012;8(12):990–8.CrossRefGoogle Scholar
  44. 44.
    McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75(1):38–50.CrossRefGoogle Scholar
  45. 45.
    Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003;300(5625):1527–8.CrossRefGoogle Scholar
  46. 46.
    Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015;75(1):68–78.CrossRefGoogle Scholar
  47. 47.
    Wills-Karp M, Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal. 2008;1(51):pe55.CrossRefGoogle Scholar
  48. 48.
    Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110.CrossRefGoogle Scholar
  49. 49.
    Bao L, Shi VY, Chan LS. IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis. Cytokine. 2013;61(2):419–25.CrossRefGoogle Scholar
  50. 50.
    Izuhara K, Arima K, Yasunaga S. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. Curr Drug Targets Inflamm Allergy. 2002;1(3):263–9.CrossRefGoogle Scholar
  51. 51.
    Gooderham MJ, Hong HC-H, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28–36.CrossRefGoogle Scholar
  52. 52.
    Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7–12.CrossRefGoogle Scholar
  53. 53.
    Howell MD, Fairchild HR, Kim BE, Bin L, Boguniewicz M, Redzic JS, et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol. 2008;128(9):2248–58.CrossRefGoogle Scholar
  54. 54.
    Hönzke S, Wallmeyer L, Ostrowski A, Radbruch M, Mundhenk L, Schäfer-Korting M, et al. Influence of Th2 cytokines on the cornified envelope, tight junction proteins, and ß-defensins in filaggrin-deficient skin equivalents. J Invest Dermatol. 2016;136(3):631–9.CrossRefGoogle Scholar
  55. 55.
    Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7(10):1043–58.CrossRefGoogle Scholar
  56. 56.
    Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, et al. TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol. 2014;134(7):1941–50.CrossRefGoogle Scholar
  57. 57.
    Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol Baltim Md 1950. 2008;181(10):7420–7.Google Scholar
  58. 58.
    Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol Baltim Md 1950. 2003;171(6):3262–9.Google Scholar
  59. 59.
    Kisich KO, Howell MD, Boguniewicz M, Heizer HR, Watson NU, Leung DYM. The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J Invest Dermatol. 2007;127(10):2368–80.CrossRefGoogle Scholar
  60. 60.
    Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151–60.CrossRefGoogle Scholar
  61. 61.
    Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol. 2001;116(5):658–63.CrossRefGoogle Scholar
  62. 62.
    Dupilumab. FDA [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761055Orig1s000MedR.pdf. Accessed 15 Jan 2019.
  63. 63.
    Dupixent-epar-product-information_es.pdf [Internet]. Available from: https://www.ema.europa.eu/documents/product-information/dupixent-epar-product-information_es.pdf. Accessed 15 Jan 2019.
  64. 64.
    Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23–31.CrossRefGoogle Scholar
  65. 65.
    Shirley M. Dupilumab: First Global Approval. Drugs. 2017;77(10):1115–21.CrossRefGoogle Scholar
  66. 66.
    Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet Lond Engl. 2016;387(10013):40–52.CrossRefGoogle Scholar
  67. 67.
    Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016;75(3):506–15.CrossRefGoogle Scholar
  68. 68.
    Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2017;389(10086):2287–303.CrossRefGoogle Scholar
  69. 69.
    de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–101.CrossRefGoogle Scholar
  70. 70.
    Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NMH, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–8.CrossRefGoogle Scholar
  71. 71.
    Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.CrossRefGoogle Scholar
  72. 72.
    Search of: Dupilumab | Atopic Dermatitis - List Results - ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/results?cond=Atopic+Dermatitis&term=Dupilumab&cntry=&state=&city=&dist=. Accessed 20 Dec 2018.
  73. 73.
    •• Han Y, Chen Y, Liu X, Zhang J, Su H, Wen H, et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2017;140(3):888–91 e6. This paper includes the first systematic analysis and comparison of published dupilumab trials data for the treatment of moderate-to-severe AD.Google Scholar
  74. 74.
    Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62–69.e1.CrossRefGoogle Scholar
  75. 75.
    Wang F-P, Tang X-J, Wei C-Q, Xu L-R, Mao H, Luo F-M. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190–8.CrossRefGoogle Scholar
  76. 76.
    Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet Lond Engl. 2016;388(10039):31–44.CrossRefGoogle Scholar
  77. 77.
    Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66.CrossRefGoogle Scholar
  78. 78.
    Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–79.CrossRefGoogle Scholar
  79. 79.
    Ridgway A, Laws P. Real world experience of dupilumab treatment for atopic dermatitis. París: EADV congress; 2018.Google Scholar
  80. 80.
    Treister AD, Lio PA. Long-term off-label dupilumab in pediatric atopic dermatitis: a case series. Pediatr Dermatol. 2018;36(1):85–8.CrossRefGoogle Scholar
  81. 81.
    Ruiz-Villaverde R, Domínguez-Cruz J, Armario-Hita JC, Martinez-Pilar L, Alcantara-Luna S, Pereyra-Rodriguez JP. Tratamiento de Dermatitis Atópica con Dupilumab en práctica clínica real. (AEDV, Palma de Mallorca congress 2018).Google Scholar
  82. 82.
    Servando E, Moya M. PROs of atopic dermatitis patients treated with dupilumab. París: EADV congress; 2018.Google Scholar
  83. 83.
    Olmos Alpiste F, Serra-Baldrich E, Figueras-Nart I, et al. Treatment of moderate to severe atopic dermatitis with dupilumab in the clinical practice. Paris: EADV congress; 2018.Google Scholar
  84. 84.
    Ruiz-Villaverde R, Dominguez-Cruz J, Armario-Hita JC, Martinez-Pilar L, Alcantara-Luna S, Pereyra-Rodriguez JJ. Dupilumab: short-term effectiveness and security in real clinical practice - a retrospective multicentric study. J Eur Acad Dermatol Venereol JEADV. 2019;33(1):e21–2.CrossRefGoogle Scholar
  85. 85.
    Rial MJ, Barroso B, Sastre J. Dupilumab for treatment of food allergy. J Allergy Clin Immunol Pract. 2019;7(2):673–4.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Milagros Lázaro-Sastre
    • 1
  • Asunción García-Sánchez
    • 2
    • 3
    Email author
  • Aída Gómez-Cardeñosa
    • 4
  • Ignacio Dávila
    • 1
    • 2
    • 3
  1. 1.University HospitalSalamancaSpain
  2. 2.Department of Biomedical and Diagnostic Sciences, Faculty of MedicineUniversity of SalamancaSalamancaSpain
  3. 3.IBSAL, Institute of Biomedical Research of SalamancaSalamancaSpain
  4. 4.Fundación Jiménez DíazMadridSpain

Personalised recommendations